🇺🇸 FDA
Pipeline program

Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)

KLWS-V502-02

Phase 2 mab completed

Quick answer

Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli) for Human Papilloma Virus Infection is a Phase 2 program (mab) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
BRIGHT MINDS BIOSCIENCES INC.
Indication
Human Papilloma Virus Infection
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials